In a move reminiscent of past trade disputes, China appears to have launched a price war on key active pharmaceutical ...

US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE ...

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Andembry (garadacimab) for the prevention of recurrent attacks of hereditary angioedema ...

US biotech Biogen has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics, a company the ...

South Korean biotech CorestemChemon (Kosdaq: 166480) has shared Phase III ALSummit trial findings for its autologous stem ...

Portuguese venture firm Biovance Capital Partners has led a series A financing for Mondego Bio, joined by US investors ...

US drugmaker Eli Lilly’s battle for dominance of the GLP-1 weight loss and diabetes market with Novo Nordisk is becoming an epic.

US biotech Arvinas today provided an update on its 2021 collaboration with pharma giant Pfizer for the co-development of ...

California, USA-based liver specialist 89bio saw its shares rocket more than 83% to $14.83 in pre-market activity on the news ...

Deciphera, a subsidiary of Japan’s Ono Pharmaceutical, has received approval from the European Commission (EC) for Romvimza (vimseltinib) for the treatment of adult patients with symptomatic ...

Regeneron Pharmaceuticals has announced the primary endpoint was met in the Phase III OPTIMA trial investigating garetosmab ...

China’s Mabwell (688062.SH) and Californian biotech venture firm Aditum Bio have combined to launch Kalexo Bio.